vs
Side-by-side financial comparison of Incannex Healthcare Inc. (IXHL) and Medicus Pharma Ltd. (MDCX). Click either name above to swap in a different company.
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical firm developing proprietary cannabinoid and psychedelic-derived therapies for unmet medical needs in respiratory, neurological, and inflammatory disorder segments. It advances its pipeline via global clinical trials to secure regulatory approvals for commercialization.
IXHL vs MDCX — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $11.6K |
| Net Profit | $-4.0M | $-20.9M |
| Gross Margin | — | — |
| Operating Margin | — | -0.1% |
| Net Margin | — | -180917.3% |
| Revenue YoY | — | -79.2% |
| Net Profit YoY | 34.2% | -818.7% |
| EPS (diluted) | $-0.20 | $-1.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $11.6K | ||
| Q2 25 | — | $40.0K | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $12.0K | — | ||
| Q3 24 | $74.0K | $55.5K |
| Q3 25 | — | $-20.9M | ||
| Q2 25 | — | $-6.2M | ||
| Q1 25 | $-4.0M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $-5.4M | $-2.3M |
| Q3 25 | — | -0.1% | ||
| Q2 25 | — | -15038.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | -41700.0% | — | ||
| Q3 24 | -8451.4% | -4204.8% |
| Q3 25 | — | -180917.3% | ||
| Q2 25 | — | -15438.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | -49116.7% | — | ||
| Q3 24 | -7324.3% | -4104.8% |
| Q3 25 | — | $-1.12 | ||
| Q2 25 | — | $-0.43 | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.33 | — | ||
| Q3 24 | $-0.29 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.7M | $8.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.4M | $-910.1K |
| Total Assets | $16.2M | $10.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $8.7M | ||
| Q2 25 | — | $9.7M | ||
| Q1 25 | $6.7M | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $3.6M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $2.4M | — | ||
| Q3 24 | — | — |
| Q3 25 | — | $-910.1K | ||
| Q2 25 | — | $3.2M | ||
| Q1 25 | $7.4M | — | ||
| Q4 24 | $964.0K | — | ||
| Q3 24 | $6.6M | $4.8M |
| Q3 25 | — | $10.0M | ||
| Q2 25 | — | $11.9M | ||
| Q1 25 | $16.2M | — | ||
| Q4 24 | $11.1M | — | ||
| Q3 24 | $16.0M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.47× | — | ||
| Q3 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.2M | $-6.8M |
| Free Cash FlowOCF − Capex | $-9.2M | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-6.8M | ||
| Q2 25 | — | $-5.5M | ||
| Q1 25 | $-3.2M | — | ||
| Q4 24 | $-5.6M | — | ||
| Q3 24 | $-2.2M | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-9.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
